by Stemedix | Nov 1, 2021 | Stem Cell Therapy, Multiple Sclerosis, Stem Cell Research
In a recent study, researchers discovered a breakthrough against MS, stem cell therapy might be able to help individuals who have multiple sclerosis (MS). The study was conducted by Italian researchers and included a group of 210 MS patients suffering from aggressive cases of the neurodegenerative condition.
The study spanned over two decades, during which time participants received multiple stem cell transplants. Roughly 140 participants did not experience further degeneration ten years after starting stem cell therapy. The majority of the patients involved in the study were diagnosed with relapsing-remitting MS, the most common type.
Are These Study Results Conclusive?
While the results from this groundbreaking study are promising, they cannot be considered “conclusive.” For instance, many researchers are still unsure which MS patients are most likely to benefit from stem cell therapy. More research is necessary to determine stem cell therapy’s overall effectiveness and identify other relevant factors.
In addition, this study is not considered a clinical trial. This is because stem cell therapy was not tested against traditional multiple sclerosis medications. All participants received stem cell therapy from different medical centers throughout Italy.
A more stringent clinical trial will reveal additional details about the efficacy of stem cell therapy for MS treatments. Additional research will help medical professionals identify who is best suited for stem cell therapy and when they should undergo this intervention. This research aims to determine if stem cells will stimulate the patient’s natural immune system so that it can begin functioning normally again. This could result is a breakthrough against MS!
How Stem Cells May Be Able to Help MS Sufferers
Human MSCs (mesenchymal stem cells) are adult stem cells found in various body tissues. This includes the bone marrow, adipose tissue, and umbilical cord tissues. MSCs have the potential to help patients suffering from a wide array of medical conditions, including MS.
Since stem cells serve as the building blocks for the immune system, this intervention could potentially stimulate natural healing. By injecting the patient with MSCs derived from bone marrow aspirate or adipose tissue, clinicians may be able to reduce the severity of symptoms. Stem cell therapy might be able to slow the progression of the condition, but these benefits are still undergoing research.
Patients suffering from MS and searching for a breakthrough against MS and an alternative treatment option may want to consider stem cell therapy, as the potential benefits greatly outweigh any risks associated with the treatment. If you would like to learn more, contact us today to speak with a care coordinator.
by admin | Oct 29, 2021 | Mesenchymal Stem Cells, Neurodegenerative Diseases, Stem Cell Research, Stem Cell Therapy
Neurodegenerative diseases affect over 50 million Americans each year and occur as a result of nerve cells in the brain, peripheral nervous system, and the central nervous system slowly and progressively losing function before eventually dying[1].
Although there are over 600 known neurological disorders, the most common neurodegenerative diseases continue to be Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and Amyotrophic lateral sclerosis (ALS).
While significant progress has been made in identifying mechanisms and risk factors contributing to the cause and development of these various neurodegenerative diseases, evidence continues to indicate that many of these conditions are influenced by oxidative stress. Research has also shown that antioxidants, the only strategy used to address this mechanism to date, have been demonstrated to be ineffective and, in some instances, even causing additional side effects.
In addition, although progress has been made in the overall understanding and management of several side effects associated with conditions contributing to neurodegeneration and that multifactor intervention introduced at an early stage is believed to be most successful, research has yet to identify a way to slow the progression of these debilitating conditions.
As part of this review, Angeloni et al. provide an analysis of recent literature examining the role of oxidative stress in several neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS, retinal ganglion cells, and ataxia. The authors also discuss the emerging role of mesenchymal stem cells (MSC) and their potential in fighting oxidative stress and enhancing antioxidant capacity and neurotrophin expression.
Recent literature concludes that oxidative stress has a significant role in each of the neurodegenerative diseases mentioned above. Specifically, oxidative stress has been found to:
- Play a fundamental role in Alzheimer’s disease, affecting different pathways involved in AD brain cells.
- Have a causal role and also be a result of different pathologies in PD.
- Be both a cause and consequence of impaired function related to ALS.
- Be a significant cause of damage in a number of ocular neurodegenerative diseases, including diabetic retinopathy, glaucoma, and retina ischemia-reperfusion injury.
- Increase ROS production linked to mitochondrial dysfunction in ataxia cell models.
The literature also indicates that MSC therapy can be a promising future management tool for neurodegenerative disease that enhances antioxidant capacity, increases neurotrophin expression, inhibits pro-inflammatory cytokine secretions, and counteracts microglial ROS production.
However, the authors also conclude that while the role of MSCs in counteracting oxidative stress-related neurodegeneration, additional studies demonstrating a more neurodegenerative disease-specific therapeutic MSC strategy for preventing a broad range of previously mentioned disorders are needed.
Accordingly, these future studies will be useful in helping to discover the appropriate numbers of MSCs needed for transplantation, realize optimal timing of transplantation, identify the correct disease stage for transplantation, and better understand the safety, functionality, recovery, and motor and cognitive improvements of various MSCs used in this process.
Source: (2020, May 7). Role of Mesenchymal Stem Cells in Counteracting Oxidative Stress …. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246730/
[1] “Neurodegenerative Diseases: An Overview of Environmental Risk ….” https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1280411/. Accessed 18 Oct. 2021.
by admin | Oct 22, 2021 | Mesenchymal Stem Cells, Stem Cell Research, Stem Cell Therapy
Since their discovery in 1960, mesenchymal stem cells (MSCs) have been found to migrate to assist and support the repair of injured tissue. In addition, and more importantly, MSCs have demonstrated therapeutic effects resulting from their ability to modulate various cells found in both the innate and adaptive immune systems.
To date, over 900 clinical trials have used MSCs to explore various diseases ranging from bone/cartilage repair, diabetes, cardiovascular diseases, immune-related, and neurological disorders by promoting neovascularization, increasing angiogenesis, enhancing cell viability, and inhibiting cell death.
While there have been promising results from animal studies, further research is taking place to determine the therapeutic efficacy of MSCs. Fan et al.’s review summarizes the progress of specific mechanisms underlying the tissue regenerative properties and immunomodulatory effects of MSCs and provides an overview of the current research on the rapid development of MSC-based therapies.
According to Fan et al., the therapeutic potential of MSCs is attributed to two specific aspects: replacement of the damaged tissue through differentiating into various cell lineages and regulation of immune response by immunomodulatory function. The major mechanism underlying MSC-based therapy appears to be the paracrine function, which allows for reduction of inflammation and increased cell proliferation while the tissue is being repaired.
Additionally, MSCs have been well demonstrated to have exceptional potential for differential. Upon transplantation, MSCs’ ability to differentiate appears to be the key to successful integration into the tissue of the host. Their ability to differentiate also appears to depend on factors such as donor age, tissue origin, cell passage numbers, cell densities, and duration of cell culture, so the authors are calling for further study to better understand the mechanisms of regulatory pathways and to improve differentiation efficacy.
Although MSC-based therapies have demonstrated significant progress, a full understanding of the ability of MSCs has made it a challenge to advance into daily clinical application. According to this review, the key factors for this happening appear to be large variability in important factors, such as cell source, dosage, administration route, and timing of the administration.
Since inconsistencies among these factors appear to affect the therapeutic value of MSCs, the authors call for standardization of procedures of MSC isolation and expansion in future clinical therapies. The authors also point out that the therapeutic potentials of MSCs are attributed to complex cellular and molecular mechanisms of action which require additional in-depth exploration for clinical application.
MSCs have been demonstrated to be an important source of stem cell therapies. However, there is still a need for additional large-scale, randomized, blinded, and controlled trials to fully demonstrate the therapeutic benefits associated with MSCs. As a result of this review, Fan et al. conclude that further clarification of the predominant mechanisms in different situations is an important step in improving the safety, efficacy, and outcomes of MSC-based therapies.
Source: (n.d.). Mechanisms underlying the protective effects of mesenchymal stem …. from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223321/
by admin | Oct 8, 2021 | Stem Cell Therapy, Exosomes, Parkinson's Disease, Stem Cell Research
Parkinson’s disease (PD) is a debilitating neurodegenerative disorder that currently affects nearly 6 million people worldwide and is currently the second most common neurological condition, behind only Alzheimer’s.
Although the exact cause of PD remains unclear, the condition is characterized by the gradual loss of nerve cells in the brain responsible for producing the neurotransmitter dopamine[1]. While no cure for PD currently exists, current therapeutic treatment approaches focus on improving quality of life but are not able to prevent or slow the progression of the disease.
Recent research has demonstrated positive effects of mesenchymal stem cell (MSC) transplantation that has been associated with secromes; noted beneficial effects include providing a self-regulated regenerative response that limits the area of lesions. Additionally, these MSC-derived secretomes compose soluble factors and encapsulated extravesicles (EV). These EVs have been found to have a significant impact on physiological processes, including cell-to-cell communication.
Considering MSCs are readily available and easily isolated from a number of sources, including adipose tissue, umbilical cord Wharton’s Jelly, bone marrow, and dental pulp, these stem cells are thought to hold potential as a therapeutic approach to managing PD.
As part of this review, d’Angelo et al. highlight a number of studies demonstrating the potential of MSCs in improving a number of conditions and symptoms consistent with those demonstrated in PD. In these studies, animal models demonstrate improved motor behaviors and correction of functional impairment after transplantation of MSCs.
The authors point out that further research exploring cell-free, therapeutic, personalized approaches for the different neurodegenerative diseases, including PD, is needed.
d’Angelo et al. also note that, while MSC-derived secretomes have shown positive effects on neuronal cell survival, differentiation, and proliferation, further studies are needed to fully understand all of the bioactive molecules.
Since MSC-derived secretomes are able to stimulate neurotrophic and neuronal survival pathways and appear to counteract neuronal death, they could potentially be a beneficial tool in future management and prevention efforts for a number of neurodegenerative conditions, including Parkinson’s disease, Alzheimer’s disease, and stroke.
Source:(2020, July 23). Insights into the Effects of Mesenchymal Stem Cell-Derived … – NCBI. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432166/
[1] “Parkinsonfoundation.org -.” https://parkinsonfoundation.org/. Accessed 5 Oct. 2021.
by admin | Oct 1, 2021 | Stem Cell Therapy, Osteoarthritis, PRP, Stem Cell Research
With nearly 30 million people in the US affected by osteoarthritis (OA), the condition continues to be among the leading causes of chronic pain and disability. Considering that advances in medical technology have increased overall life expectancy, the number of people living longer and dealing with the effects of OA is expected to increase for the foreseeable future.
Although modern medicine has improved the way most diseases and chronic conditions are diagnosed and treated, OA treatment has not benefited from these advances. As a result, treatment and prevention of OA continue to focus primarily on controlling and minimizing symptoms associated with the condition, not treating or preventing the condition itself. Unfortunately, for many, when symptoms of OA progress to a point where the pain is no longer able to be managed, their options look to surgical replacement of the affected joint.
While there are many contributing factors related to the onset and progression of OA, including obesity, history of trauma, genetics, and heritable and acquired disorders, there also appears to be an association between the onset of OA and a depleted local population of mesenchymal stem cells (MSCs).
Considering the apparent relationship between OA and MSCs, Freitag et al. reviewed the reparative pathways, safety, and efficacy of MSC therapy in the treatment of osteoarthritis.
With their ease of harvest and ability to expand into chondrocytes, MSCs have continued to gain interest when exploring various stem cell therapies for the active management of pain and symptoms associated with OA.
Freitag et al. found that preclinical and clinical results of studies of cartilage repair techniques that utilize MSCs, including MSC scaffold transplantation techniques, MSC injectable techniques, MSC as a vehicle for platelet-rich plasma (PRP), and hyaluronic acid (HA) as an active carrier of MSCs, have all shown favorable results in supporting the benefits of MSC for the improvement of function and regeneration of new tissue in those afflicted with OA.
With over 400 active trials currently examining the efficacy of MSCs in the treatment of a variety of conditions, including OA, the safety of utilizing MSC therapy continues to draw interest from the medical community.
Although some early studies appeared to raise the question of abnormal cell growth, and ultimately the safety, associated with MSC therapy, the authors’ systematic review of clinical trials found that, while caution needs to be undertaken when culturing MSCs, the evidence demonstrates MSCs are generally safe for therapeutic use for the treatment of OA.
Freitag et al. conclude that the rapid progression of OA and related conditions demonstrate the need for therapies that repair and prevent these diseases, not just manage pain and related symptoms. As such, the authors feel MSC therapy offers a safe and viable option for the eventual treatment and prevention of OA and calls for further randomized controlled trials to evaluate the most effective applications of MSCs for managing osteoarthritis.
Source: (2016, May 26). Mesenchymal stem cell therapy in the treatment of osteoarthritis. Retrieved from https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-016-1085-9
by admin | Sep 3, 2021 | Stem Cell Therapy, Mesenchymal Stem Cells, Stem Cell Research
Human mesenchymal stem cells (hMSCs) are multipotent adult stem cells found in tissue throughout the body, including in the umbilical cord, bone marrow, and adipose tissue. Capable of self-renewing and differentiating into multiple tissues including bone, cartilage, muscle, fat cells, and connective tissue[1], MSCs appear to have a wide range of potential for use as therapeutic purposes for many serious health problems occurring throughout the body.
In this review, Rodriguez-Fuentes et al. examined currently registered (as of July 2020) clinical trials involving mesenchymal stem cells with the goal of analyzing the different applications of MSCs in a clinical setting to demonstrate the growing and broad potential of their therapeutic application relative to the reconstruction of damaged tissue.
As of July 2020, the authors identified 1,138 registered clinical trials (CTs) worldwide using MSCs to investigate their therapeutic potential. Therapeutic applications are a relatively new area of study, evidenced by the fact that only 19 CT studies were started between 1995 and 2005 and over 900 were initiated in the last ten years (2011-present). The majority of these CTs focused on the fields of traumatology, neurology, cardiology, and immunology. Interestingly, of the 1,138 CTs identified in this query, only 18 had published outcomes.
Examining the global distribution of registered CTs, it was observed that CTs are located in 51 countries, with China (228) and the US (186) leading the research.
As part of this review, and in addition to examining the number and geographic locations of registered CTs, the sourcing, isolation and treatment methods, and storage conditions of MSCs used in each clinical trial.
Most of the MSCs used for these CTs were obtained from cells of the iliac crest, placenta, and adipose tissue. All recovered cells underwent steps of purification and expansion prior to use in patients. Additionally, all methods used in these CTs were also found to follow good manufacturing practices (GMP).
Upon completing their review of registered CTs, Rodriguez-Fuentes et al. also observed that medical specialties for the most published studies included (in descending order) cardiology, traumatology, pneumology, neurology, hematology, ophthalmology, and plastic surgery. The most frequent pathologies addressed in these published CT studies included knee osteoarthritis, ischemic heart disease, and dilated cardiomyopathy. While the number of MSCs used varied by study, most utilized around 100 million MSCs.
The authors concluded that most studies analyzed as part of this review demonstrate positive outcomes with no serious adverse effects. While China and the US lead the world in the number of registered MSC clinical trials, the authors point out the fact that many of these CTs have multiple locations in different countries – indicating the importance of, and willingness to, collaborate internationally on this research.
Although most of the conditions for which clinical utility of MSCs have been published are conditions that do not currently have specific treatments with desirable or effective outcomes, there appears to be significant and broad potential for the clinical use of hMSCs without serious adverse events.
While there are currently at least 1,138 registered MSC CTs, there is still much to be examined and understood about MSCs. As such the continually increasing number of CTs including MSCs will help identify and demonstrate the therapeutic potential of these versatile stem cells.
[1] “Mesenchymal stem cells – Latest research and news | Nature.” https://www.nature.com/subjects/mesenchymal-stem-cells.
Source: Mesenchymal Stem Cells Current Clinical Applications. From https://www.sciencedirect.com/science/article/pii/S018844092030638X
St. Petersburg, Florida
